UCB PHARMA, S.A. Patent applications |
Patent application number | Title | Published |
20150045734 | AUTO-INJECTOR - Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity is arranged for receipt of a syringe suitable for delivery of a drug to a patient. The syringe has a barrel for containing a volume of a liquid drug formulation, the barrel defining a flange at the rear end thereof and a forward shoulder at the forward end thereof. The cassette unit includes one or more shoulder support features for supporting the forward shoulder of the syringe. In use, the one or more shoulder support features act to direct a major part of an applied load path to travel through the shoulder at the forward end of the syringe and lesser load to pass through the flange at the rear end thereof. | 02-12-2015 |
20140358085 | AUTO-INJECTOR - There is provided a cassette unit that is suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe that is suitable for use in the injected delivery of drug to a patient. The cassette unit includes a removable cap that fits over and thereby, acts such as to close off the needle projection aperture; and connecting to the removable cap, a needle cover defining a needle sheath for sheathing of the needle tip of the syringe. The removable cap is provided with a finger-grip feature that is sized and shaped for gripping by the finger of a user to allow for removal of the removable cap and needle cover from the cassette unit housing. | 12-04-2014 |
20140358084 | AUTO-INJECTOR - There is provided a cassette unit that is suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe that is suitable for use in the injected delivery of drug to a patient. The cassette unit includes a removable cap that in a capping position fits over and thereby, acts such as to close off, the needle projection aperture. The cassette unit includes a cap lock feature movable from a first cap locking position in which it prevents removal of the removable cap from the capping position with the cassette unit to a second cap non-locking position in which it no longer prevents such cap removal. | 12-04-2014 |
20140358083 | AUTO-INJECTOR - Provided is an auto-injector for a syringe suitable for the injected delivery of drug to a patient. The auto-injector comprises a cassette unit arranged for receipt of a syringe. The cassette unit and/or syringe is movable from a rest position, in which the syringe needle tip is within the drive unit housing to a use position, in which the needle tip protrudes from a needle delivery aperture thereof. The auto-injector comprises a drive unit arranged for docking receipt of the cassette unit at a docking position and a drive arrangement. The drive unit is arranged for initial receipt of the cassette unit at an intermediate pre-docking position and for subsequent transport of the cassette unit to the docking position. In embodiments, the drive unit is arranged such that transport of the cassette unit to the docking position is permitted only following verification of an identifier at the intermediate pre-docking position. | 12-04-2014 |
20140358072 | AUTO-INJECTOR - There is provided an auto-injector for a syringe that is suitable for use in the injected delivery of drug to a patient. The auto-injector comprises a cassette unit arranged for receipt of a syringe provided with a needle cover and removable cap. The auto-injector also comprises a drive unit arranged for docking receipt of the cassette unit at a docking position and a drive arrangement. The drive unit is provided with a timer that starts a time count on removal of the removable cap and needle cover from the cassette unit. | 12-04-2014 |
20140356911 | Method for Producing Protein - The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell. | 12-04-2014 |
20140348844 | NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE - This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of | 11-27-2014 |
20140342406 | DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES | 11-20-2014 |
20140336588 | AUTO-INJECTOR - Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity is arranged for receipt of a syringe for injected delivery of a drug to a patient. The cassette unit includes a removable cap that in a capping position fits over and thereby acts to close off the needle projection aperture; and connecting to the removable cap, a needle cover defining a needle sheath for sheathing the needle tip of the syringe. The removable cap is provided with one or more first engagement features arranged for selectively engaging one or more second engagement features of the cassette unit housing when the removable cap is in the capping position to thereby restrict/prevent rotation of the removable cap and needle cover relative to the housing. | 11-13-2014 |
20140336587 | AUTO-INJECTOR - Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity is arranged for receipt of a syringe suitable for use in the injected delivery of drug to a patient. The syringe has a barrel for containing a volume of a liquid drug formulation, the barrel defining an end flange at the rear end thereof and a forward shoulder at the forward end thereof. The cassette unit includes a sleeve form adapter arranged for receipt by the syringe barrel and to fit at least partly over the end flange of the syringe barrel. Accommodation of different syringe sizes within the same cassette unit geometry is achievable by selecting a sleeve form adapter tailored to the particular sizing of the barrel of each different syringe. | 11-13-2014 |
20140330207 | AUTO-INJECTOR - Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe suitable for use in the injected delivery of drug to a patient. The cassette unit includes a needle cover defining a needle sheath. The removable cap is provided with a connector defining one or more needle cover gripping elements for gripping the needle cover. The connector defines a central hub and the one or more needle gripper elements attach to the central hub and in spaced arrangement relative to each other. The connector locates within the removable cap such that the central hub of the connector is in spaced relationship with a far end wall or surface of the cap interior. | 11-06-2014 |
20140330203 | AUTO-INJECTOR - Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe. The syringe has a barrel for containing a volume of a liquid drug formulation, the barrel defining a flange at the rear end thereof and a forward shoulder at the forward end thereof; a hollow needle at a front end of the barrel, the hollow needle defining a needle tip; and a plunger that is axially movable within the barrel. The cassette unit includes, in contact with the plunger and axially movable within the barrel, a plunger slaving part arranged such that when a drive load is applied to a rear drive-receiving face thereof the drive load is evenly transmitted to the plunger. | 11-06-2014 |
20140309222 | Therapeutically Active Fused Pyrimidine Derivatives - A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection. | 10-16-2014 |
20140302033 | ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF - A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same. | 10-09-2014 |
20140257192 | SYSTEMS AND METHODS FOR ADMINISTERING MEDICATION - The syringe systems disclosed herein provide in part devices for allowing patients with compromised joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a handle forming a handgrip, a syringe barrel that magnifies the dosage marks located on an inner barrel, and a tip cap slidably engageable with the syringe barrel for shielding a needle. | 09-11-2014 |
20140242625 | ANALYTICAL METHOD FOR FAB AND FAB' MOLECULES - A method of measuring acidic species generated by degradation of a Fab or Fab′ component of a Fab-PEG or a Fab′-PEG is provided. The method involves: a) cleaving PEG and a linker from the Fab-PEG or Fab′-PEG with an enzyme; b) optionally separating the PEG and linker from the Fab or Fab′ to provide isolated Fab or Fab′; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab′ and/or the cleaved PEG. | 08-28-2014 |
20140194596 | Dual Specificity Antibody Fusions - The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest. | 07-10-2014 |
20140193403 | Epitopes of IL-17A and IL-17F and Antibodies Specific Thereto - The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them. | 07-10-2014 |
20140186355 | Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 07-03-2014 |
20140178387 | ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13 - The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 06-26-2014 |
20140148489 | 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives - The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 05-29-2014 |
20140141468 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC - The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector, comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen binding fragment thereof specifically binding to CD154. | 05-22-2014 |
20140080134 | LIPOCALIN 2 AS A BIOMARKER FOR IL-17 INHIBITOR THERAPY EFFICACY - The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy. | 03-20-2014 |
20140065674 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 03-06-2014 |
20140044732 | Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 02-13-2014 |
20140030268 | TREATMENT FOR BONE DISEASES - The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody. | 01-30-2014 |
20140024077 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-6 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 01-23-2014 |
20130330344 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 12-12-2013 |
20130323236 | Antibodies of the Class IGG4 - The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a C | 12-05-2013 |
20130302336 | DISULFIDE STABILIZED DVD-IG MOLECULES - A re-epoxidized polyfunctional epoxy resin composition comprising the reaction product of: (I) an epoxidized polyfunctional epoxy resin oligomeric composition comprising a polyfunctional aliphatic or cycloaliphatic epoxy resin which has been isolated from an epoxy resin product formed as a result of an epoxidation process comprising the reaction of: (i) an aliphatic or cycloaliphatic hydroxyl-containing material; (ii) an epihalohydrin, (iii) a basic-acting substance, in the presence of (iv) a non-Lewis acid catalyst; and (v) optionally, one or more solvents; (II) an epihalohydrin; (III) a basic acting substance; in the presence of (IV) a non-Lewis acid catalyst; and (V) optionally, one or more solvents. A curable epoxy resin composition of the re-epoxidized polyfunctional epoxy resin composition and a thermoset of the curable composition is also disclosed. | 11-14-2013 |
20130296338 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors - A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 11-07-2013 |
20130245229 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 09-19-2013 |
20130243772 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 09-19-2013 |
20130203968 | ANTIBODY-BASED DIAGNOSTICS AND THERAPEUTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 08-08-2013 |
20130184439 | PROTEIN PURIFICATION - The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step. | 07-18-2013 |
20130183703 | ANALYTICAL METHOD FOR FAB AND FAB' MOLECULES - A method of measuring acidic species generated by degradation of a Fab or Fab′ component of a Fab-PEG or a Fab′-PEG comprising the steps of: a) cleaving the PEG and linker from the Fab-PEG or Fab′-PEG with an enzyme; b) optionally separating the PEG and linker generated in step a) from the Fab or Fab′, to provide a Fab or Fab′; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab′ and/or the cleaved PEG. | 07-18-2013 |
20130178607 | PROCESS FOR PURIFYING PROTEINS - The present invention provides method for purifying a recombinant protein from a gram-negative bacterial host cell sample or extract thereof wherein said host cell expresses a recombinant protein and a recombinant disulphide isomerase DsbC; comprising: a. adjusting the pH of the host cell sample or extract thereof to a pH of 5 or less to precipitate the recombinant disulphide isomerase; and b. separating precipitated recombinant disulphide isomerase DsbC from the recombinant protein to produce a recombinant protein sample. | 07-11-2013 |
20130150573 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - Novel processes for the preparation of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety and intermediates thereto are provided. The compounds prepared by the present processes may be useful, for example, as selective inhibitors of human MEK (MAPKK) enzymes, and are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability. | 06-13-2013 |
20130108622 | DISULFIDE STABILIZED ANTIBODIES AND FRAGMENTS THEREOF | 05-02-2013 |
20130102030 | Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 04-25-2013 |
20130095098 | PD-1 ANTIBODY - A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules. | 04-18-2013 |
20130079717 | SYRINGE SAFETY ASSEMBLY - Systems, devices, and methods are provided for providing safe syringe assemblies for injections. The syringe assemblies include a shielding mechanism that covers a syringe needle after an injection is delivered, thereby reducing the risk of a subsequent accidental stab from the needle. The shielding mechanism has a pre-injection configuration in which the needle extends beyond the housing and a post-injection configuration in which at least one component of the syringe assembly covers the needle. In some implementations, the syringe assembly includes a lock that inhibits the assembly from returning to the pre-injection configuration once an injection is delivered. The syringe assemblies may also include a bevel orientation mechanism that allows a user to align a needle bevel to accurately insert a needle for injection. | 03-28-2013 |
20130079330 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 03-28-2013 |
20130066054 | MULTIVALENT ANTIBODIES - A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally V | 03-14-2013 |
20130053549 | Multivalent Antibodies - The present invention provides a recombinant antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a C | 02-28-2013 |
20130045219 | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF - This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions. | 02-21-2013 |
20130018057 | Quinoline and Quinoxaline Derivatives as Kinase InhibitorsAANM Burli; RolandAACI Saffron Walden EssexAACO GBAAGP Burli; Roland Saffron Walden Essex GBAANM Haughan; Alan FindlayAACI Saffron Walden EssexAACO GBAAGP Haughan; Alan Findlay Saffron Walden Essex GBAANM Matteucci; M zioAACI Saffron Walden EssexAACO GBAAGP Matteucci; M zio Saffron Walden Essex GBAANM Owens; Andrew PateAACI Saffron Walden EssexAACO GBAAGP Owens; Andrew Pate Saffron Walden Essex GBAANM Raphy; GillesAACI Saffron Walden EssexAACO GBAAGP Raphy; Gilles Saffron Walden Essex GBAANM Sharpe; AndrewAACI Saffron Walden EssexAACO GBAAGP Sharpe; Andrew Saffron Walden Essex GB - A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-17-2013 |
20130012517 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors - A series of quinoline and quinoxaline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-10-2013 |
20130012515 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors - A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-10-2013 |
20120329774 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 12-27-2012 |
20120316324 | Disulfide Stabilised Multivalent Antibodies - A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest which are a VH/VL pair, wherein the two single domain antibodies are linked by a disulfide bond. Also provided are particular dual specificity antibody fusion proteins and other antibody fragments which are stabilised by a disulfide bond. | 12-13-2012 |
20120302790 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives - The present invention provides an alternative synthesis of N-substituted aminotetralines which synthesis comprises catalytic asymmetric hydrogenation of compounds of general formula (A). | 11-29-2012 |
20120301920 | BACTERIAL HOST STRAIN COMPRISING A MUTANT SPR GENE AND A WILD-TYPE TSP GENE - The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a mutant spr protein and wherein the cell comprises a non-recombinant wild-type chromosomal Tsp gene. | 11-29-2012 |
20120295309 | BACTERIAL HOST STRAIN COMPRISING A MUTANT SPR GENE AND HAVING REDUCED TSP ACTIVITY - The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell. | 11-22-2012 |
20120288894 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC AND HAVING REDUCED TSP ACTIVITY - The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell. | 11-15-2012 |
20120283415 | Multivalent Antibodies - The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains. | 11-08-2012 |
20120263728 | METHOD TO GENERATE ANTIBODIES TO ION CHANNELS - The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel. | 10-18-2012 |
20120263727 | METHOD TO GENERATE ANTIBODIES TO ION CHANNELS - The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel. | 10-18-2012 |
20120259096 | ANTIBODIES TO ION CHANNELS - An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies. | 10-11-2012 |
20120258492 | BACTERIAL HOST STRAIN - A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest. | 10-11-2012 |
20120245215 | Co-Crystals of Pyrrolidinones - The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R | 09-27-2012 |
20120245208 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives - The present invention relates to 2-oxo-1-pyrrolidine imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 09-27-2012 |
20120214815 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses - The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 08-23-2012 |
20120196866 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses - The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 08-02-2012 |
20120183558 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 07-19-2012 |
20120171125 | Methods for Enhancing the Cognitive Function - A compound having an affinity to a SV2 protein for the treatment of a condition associated with enhancement or improvement of the cognitive ability or to counteract cognitive decline of a mammal. For example, a compound which is covered by formula (I) R | 07-05-2012 |
20120135453 | Methods of Treatment Using CCA1 Inhibitors - Provided herein are methods for the treatment or prevention of a fungal infection in a host comprising the administration to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor. | 05-31-2012 |
20120129219 | Antibody Molecules Which Bind Human IL-17 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods of producing the antibody molecules. | 05-24-2012 |
20120095005 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors - A series of substituted pyrazolo[1,5-α][1,3,5]triazine and pyrazolo[1,5-αj-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). | 04-19-2012 |
20120094297 | Method For Producing Protein - The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell. | 04-19-2012 |
20120077815 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors - A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 03-29-2012 |
20120040401 | Method For Producing Proteins - The invention relates to a transcriptionally active recombinant linear polynucleotide encoding a multimeric protein comprising in the following order, a first promoter sequence, a first encoding polynucleotide sequence, a bidirectional regulatory sequence, a second encoding polynucleotide sequence and a second promoter sequence, wherein the first and second encoding polynucleotide sequences are in convergent transcriptional orientation, each encoding polynucleotide sequence encodes a component of the multimeric protein and the bidirectional regulatory sequence is operably linked to the first and second encoding polynucleotide sequences and the multimeric protein is an antibody or fragment thereof and each encoding polynucleotide sequence encodes one or more antibody domains or fragments thereof. | 02-16-2012 |
20120040006 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 02-16-2012 |
20120034656 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 02-09-2012 |
20120029188 | Substituted Aniline Derivatives - The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections. | 02-02-2012 |
20110313138 | Method for Producing Proteins - This invention provides a method for obtaining a recombinant antibody with a desired function, comprising: (a) providing a population of antibody-forming cells suspected of containing at least one cell capable of producing an antibody exhibiting the desired function; (b) generating one or more transcriptionally active recombinant linear polynucleotides from the antibody forming cells obtained in step (a) wherein each transcriptionally active recombinant linear polynucleotide comprises a polynucleotide sequence encoding a variable domain of an antibody produced by an antibody-forming cell obtained in step (a) and one or more transcription regulatory elements; (c) expressing a recombinant antibody using one or more of the transcriptionally active recombinant linear polynucleotides generated in step (b); (d) screening the recombinant antibody produced by step (c) for the desired function; and (e) optionally repeating steps (b), (c) and (d) to identify a recombinant antibody exhibiting the desired function. | 12-22-2011 |
20110305702 | EPITOPES - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 12-15-2011 |
20110281929 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-17-2011 |
20110275857 | Antibody-Guided Fragment Growth - The present invention relates to an improved method for drug discovery comprising using contact residue information derived from antibody-protein target interactions to help to direct the growth of small molecule fragments during the synthesis of a drug candidate. In particular, the present invention relates to the use of atomic structural information derived from anti-body-protein interactions to guide the growth of small molecular fragments during lead optimisation, thus generating small molecule compounds which can alter the biological activity of a target protein. | 11-10-2011 |
20110275693 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-10-2011 |
20110274762 | Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivate - The present invention relates to a pharmaceutical composition comprising Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation made of granules containing the active ingredient in their inner core. | 11-10-2011 |
20110262443 | Epitopes Of Il-17a And Il-17f And Antibodies Specific Thereto - The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them. | 10-27-2011 |
20110250282 | Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivative - The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 10-13-2011 |
20110201630 | Fused Pyridine Derivatives as Kinase Inhibitors - A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 08-18-2011 |
20110184152 | Biological Products - A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab′ fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween. | 07-28-2011 |
20110172191 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 07-14-2011 |
20110105508 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS - A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 05-05-2011 |
20110098300 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals, useful for the treatment and prevention of diseases or pathological conditions of the central nervous system including mild-cognitive impairments, Alzheimer's disease, learning and; memory disorders, cognitive disorders, attention deficit disorder, attention-deficit hyperactivity disorder, Parkinson's disease, schizophrenia, dementia, depression, epilepsy, seizures, convulsions, sleep/wake and arousal/vigilance disorders such as hypersomnia and narcolepsy, pain and/or obesity. | 04-28-2011 |
20110097342 | BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 04-28-2011 |
20110091547 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 04-21-2011 |
20110064808 | EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect. | 03-17-2011 |
20110064807 | EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system. | 03-17-2011 |
20110021786 | Pharmaceutical Solutions, Process of Preparation and Therapeutic Uses - The present invention concerns a stable pharmaceutical solution, a process of the preparation thereof and therapeutic uses thereof. | 01-27-2011 |
20110021558 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 01-27-2011 |
20110014271 | Substituted Aniline Derivatives - The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections. | 01-20-2011 |
20110003785 | Fused Thiazole Derivatives As Kinase Inhibitors - A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-06-2011 |
20100310564 | Method for the Treatment of Glomerulonephritis - The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide. | 12-09-2010 |
20100305116 | Compounds Comprising a Cyclobutoxy Group - The present invention relates to compounds comprising a cyclobutoxy group, processes for preparing them, phar-maceutical compositions comprising said compounds and their use as pharmaceuticals. | 12-02-2010 |
20100305066 | Fused Thiophene Derivatives as Kinase Inhibitors - A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 12-02-2010 |
20100298310 | Thiazole Derivatives as Kinase Inhibitors - A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 11-25-2010 |
20100298289 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS - The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 11-25-2010 |
20100292505 | Sulfanyl Derivatives And Their Use As Synthesis Intermediates - The present application relates to sulfanyl derivatives of formula (I) and to their use as synthesis intermediates, especially for the preparation of the pharmaceutically active compound mesna. Formula (I), wherein X is O or N—C(NH)NH | 11-18-2010 |
20100292188 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals. | 11-18-2010 |
20100285530 | E.Coli Host Cells with Modified Phos/Psts Periplasmic Phosphate-binding Proteins, and Method of Manufacturing Recombinant Fabs - The present invention provides an | 11-11-2010 |
20100266609 | Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 10-21-2010 |
20100240728 | Co-Crystals of Pyrrolidinones - The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R | 09-23-2010 |
20100239582 | Dual Specificity Antibody Fusions - The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest. | 09-23-2010 |
20100222326 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders - The present invention relates to new compounds, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 09-02-2010 |
20100179185 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof - The present invention concerns novel 3-aminothienopyridinone derivatives of the formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 07-15-2010 |
20100179124 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 07-15-2010 |
20100168077 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof - The present invention concerns 2-amino pyridine derivatives of formula 1 processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 07-01-2010 |
20100158913 | Antibody Molecules Having Specificity for Human IL-1B - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 06-24-2010 |
20100137302 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 06-03-2010 |
20100093977 | Altered Antibodies - This invention relates to engineering of antibodies and more specifically provides altered antibodies of the IgG class to which one or more effector molecules are attached. The invention further relates to methods for the production of such conjugated antibodies. | 04-15-2010 |
20100086538 | Antibody Molecules Which Bind to Human IL-17 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 04-08-2010 |
20100069375 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses - The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion. | 03-18-2010 |
20100069361 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). | 03-18-2010 |
20100036091 | ANTIBODY-BASED DIAGNOSTICS AND THERAPEUTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 02-11-2010 |
20100035863 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions - The present invention concerns novel 2 amino pyrimidine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as harmaceuticals. | 02-11-2010 |
20100016795 | SYSTEMS FOR ADMINISTERING MEDICATION - The autoinjector systems disclosed herein provide in part devices for allowing patients with reduced joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a housing, a syringe assembly slidably mounted on the housing, and a needle cap releasably engaged to the housing, where the cap includes a protruding pocket for receiving a needle cap remover. | 01-21-2010 |
20100015665 | ANTIBODIES AND DIAGNOSTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 01-21-2010 |
20100009969 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands - The present invention relates to compounds comprising fused oxazole or thiazole derivatives of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H | 01-14-2010 |
20090326203 | Framework Selection - The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks. | 12-31-2009 |
20090312333 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses - The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 12-17-2009 |
20090304713 | BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 12-10-2009 |
20090304696 | Single Chain FC Polypeptides - The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain. | 12-10-2009 |
20090264411 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS - A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 10-22-2009 |
20090239263 | Expression Control Using Antibody Expression Optimisation Sequences - The present invention provides a dicistronic message for producing an antibody molecule, in which the upstream cistron contains DNA coding for the light chain of the antibody and the downstream cistron contains DNA coding for the corresponding heavy chain, characterised in that the dicistronic message comprises a sequence selected from AEOS1 (SEQ ID NO:1), AEOS2 (SEQ ID NO:2), AEOS3 (SEQ ID NO:3), AEOS4 (SEQ ID NO: 4), AEOS5 (SEQ ID NO:5), AEOS6 (SEQ ID NO:6), AEOS7 (SEQ ID NO:7), AEOS8 (SEQ ID NO:8), AEOS9 (SEQ ID NO:9), AEOS1O (SEQ ID NO:10) and AEOS1 1 (SEQ ID NO:11). | 09-24-2009 |
20090221828 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives - A process for preparing 1-halo-2,7-naphthyridinyl derivatives is described (I), wherein X is Cl or Br; which process comprises the following steps: (i) reaction of a 3-cyano-4-methylpyridine derivative of formula (A): with a compound of formula (II), in the presence of an N,N-dimethylformamide diC | 09-03-2009 |
20090209498 | Methods of Treatment Using CCA1 Inhibitors - Provided herein are methods for the treatment or prevention of a fungal infection in a host comprising the administration to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor. | 08-20-2009 |
20090186914 | Phenylalanine Enamide Derivatives - Phenylalanine enamide derivatives of formula (1) are described: | 07-23-2009 |
20090149437 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 06-11-2009 |
20090131508 | Use of 2-Oxo-1-Pyrrolidone Derivatives for the Preparation of a Drug - The present invention relates to the use of brivaracetam for the preparation of drugs effective for the prevention or treatment of progressive myoclonic epilepsies. | 05-21-2009 |
20090123944 | Bioassays - The invention relates to vectors encoding bioassay receptors and in vitro bioassays using said bioassay receptors for assessing compounds of interest. In particular, the bioassays provide a generic platform for the comparison of binding of different ligands to their respective receptors or binding partners in the presence and/or absence of a compound of interest. | 05-14-2009 |
20090117126 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 05-07-2009 |
20090075398 | Method for Obtaining Antibodies - A method of obtaining at least one recombinant antibody with improved affinity for a selected antigen from a family of antibodies which bind the selected antigen comprising: a) obtaining a family of two or more antibodies which bind the same antigen in which the VH CDR3 amino acid sequence of each antibody in the family is the same length and greater than 60% identical at the amino acid level; b) re-pairing the VH region of an antibody obtained in step (a) with the VL region from a different antibody obtained in step (a) to produce a new recombinant antibody; and c) screening the recombinant antibody produced in step (b) and selecting said antibody if it has improved affinity for the selected antigen compared to any one of the antibodies obtained in step (a). | 03-19-2009 |
20090023708 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses - The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals. | 01-22-2009 |
20090018148 | Xanthine Derivatives, Processes For Preparing Them And Their Uses - The present invention concerns xanthine derivatives, having formula (I), processes for preparing them, pharmaccutical compositions containing them and their use as pharmaceuticals. | 01-15-2009 |
20090012313 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses - The present invention relates to 3-carboxy-2-oxo-1-pyrrolidine derivatives of formula (I), geometrical isomers, enantiomers, diastereoisomers, pharmaceutically acceptable salts and all possible mixtures thereof, and processes using them. | 01-08-2009 |
20090012147 | Indolone Derivatives, Processes For Preparing Them And Their Uses - The present invention relates to indolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 01-08-2009 |
20080306246 | Process for Attaching Effector Molecules to Proteins - The present invention provides a process for attaching one or more effector molecules to one or more cysteines in a protein comprising: a) activating one or more cysteines in the protein by diafiltering the protein against a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds and b) reacting the treated protein with an effector molecule. | 12-11-2008 |
20080306060 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 12-11-2008 |
20080275046 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses - The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H | 11-06-2008 |
20080269489 | Pyroglutamate Salts and Their Use in the Optical Resolution of Intermediates for the Synthesis of Dextrocetirizine and Levocetirizine - The present invention relates to (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide-(S)-pyrrolidone-5-carboxylic acid salt; (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide-(S)-pyrrolidone-5-carboxylic acid salt; (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide-(R)-pyrrolidone-5-carboxylic acid salt; or (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxycetamide-(R)-pyrrolidone-5-carboxylic salt. The present invention relates also to a process for preparing (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide (I) and (R)-2-[4-(4-chlorobenzhydryl) piperazin-1-yl]-ethoxyacetamide (II) by chemical resolution of a mixture. These compounds are respectively intermediates for the synthesis of dextrocetirizine and levocetirizine. | 10-30-2008 |
20080269466 | Modified Antibody Fragments - The present invention relates to a new class of modified antibody fragments. The present invention provides an antibody fragment to which one or more effector molecules is attached characterized in that the native interchain disulphide bond between the heavy (CHI) and light (CL) chain constant regions is absent and the heavy chain (CHI) and light chain (CL) constant regions are linked by an interchain disulphide bond between a pair of engineered cysteines, one in the light chain constant (CL) region and the other in the heavy chain constant (CHI) region. | 10-30-2008 |
20080269465 | BIOLOGICAL PRODUCTS - There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα. | 10-30-2008 |
20080269316 | Pharmaceutical Compositions Comprising Levetiracetam and Process for Their Preparation - The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation. | 10-30-2008 |
20080220005 | Comb Polymers - The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B | 09-11-2008 |
20080207907 | Process For Pd-Catalysed C-N Coupling In Specific Solvent Systems - The invention relates to a novel process for the Pd catalysed formation of C—N bonds between an aryl halide or an aryloxysulphonyl compound and an amine in specific solvent systems, and also to the use of these solvent systems for C—N couplings. | 08-28-2008 |